Abstract Library

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,

#3571 A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study)

Introduction: No standard 2nd line treatment has been validated in patients (pts) with metastatic or locally advanced, non-resectable, grade 3 gastroenteropancreatic (GEP) and lung NEC after first-line platinum therapy. Furthemore more accurate prognostic biomarkers are needed.

Conference:

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Foca F, Bergamo F, Leo S, Pusceddu S,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, second line, Phase 2, NEC, Temozolomide, Capecitabine,

#3476 A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy

Introduction: Second-line treatment for neuroendocrine carcinoma (NEC) have been investigated in prospective trials, with only few prospective trials ongoing. Therefore, there is no consensus on the second-line regimen to use in patients with progressive NEC. These patients have generally a poor performance status (PS) and the tolerance to combination therapy is low. Metronomic temozolomide showed, in retrospective trials, a good safety and efficacy profile.

Conference:

Presenting Author:

Authors: Cannella L, von Arx C, Bracigliano A, Pizzolorusso A, Antonella D,

Keywords: neuroendocrine, temozolomide, NEC, Treatment,

#3209 Irinotecan and oxaliplatin based regimens of second-line treatment in gastrointestinal neuroendocrine carcinoma (GI-NEC) patients: A retrospective study

Introduction: Determination of second line treatment in metastatic gastrointestinal neuroendocrine carcinoma (GI-NEC) remains in controversy.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhang J, Li J, Lu M, Shen L,

Keywords: gastrointestinal neuroendocrine carcinoma, second-line treatment, survival analysis, overall response rate,

#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Cameselle-Garcia S, Sardo E, Landolfi S, Merino-Casabiel X, Sánchez J,

Keywords: Neuroendocrine Neoplasms, Inflammatory Biomarkers, Gastroenteropancreatic,